Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
The STOP Program recruits and trains international public health consultants.
Original title: “STOP Program”
Line graphs show provisional estimates of infant, neonatal, and postnatal deaths and death rates for the 5 leading causes of death—updated quarterly
Original title: “Infant Mortality Dashboard”
DOSE-SYS captures electronic health record information in syndromic surveillance systems.
Original title: “DOSE-SYS Dashboard: Nonfatal Overdose Syndromic Surveillance Data”
Countries with evidence of chikungunya transmission. Some U.S. travelers may consider vaccination.
Original title: “Areas at Risk for Chikungunya”
Quarterly Provisional Estimates - Infant Mortality
Original title: “Quarterly Provisional Estimates of Infant Mortality, 2023-Quarter 2, 2025”
The Department of Health and Human Services (HHS) is updating its regulations to reflect required annual inflation-related increases to the civil monetary penalty (CMP) amounts in its statutes and regulations, under the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015.
Original title: “Annual Civil Monetary Penalties Inflation Adjustment”
The Administration for Children and Families (ACF) proposes to extend approval of the existing overarching generic clearance for Reviewer Recruitment Forms (Office of Management and Budget (OMB) #0970-0477). No changes are proposed to the terms of the overarching generic. Burden estimates have been updated.
Original title: “Proposed Information Collection Activity; Generic Clearance for Reviewer Recruitment Forms”
Original title: “Obesity and Overweight”
The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR) hereby rescinds "Guidance to Nation's Retail Pharmacies: Obligations under Federal Civil Rights Laws to Ensure Nondiscriminatory Access to Health Care at Pharmacies," issued on September 29, 2023 (2023 Guidance) as revised guidance to "Guidance to Nation's Retail Pharmacies: Obligations under Federal Civil Rights Laws to Ensure Access to Comprehensive Reproductive Health Care Services," originally issued on Jul
Original title: “Rescission of Guidance to Nation's Retail Pharmacies: Obligations Under Federal Civil Rights Laws To Ensure Nondiscriminatory Access to Health Care at Pharmacies (Issued September 29, 2023)”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZDIFFRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; REZDIFFRA”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXBLIFEP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; EXBLIFEP”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BIMZELX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; BIMZELX”
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comments on a proposed information collection project titled Survey to Promote Resources and Opportunities for aUtistic Teens and young adults (SP
Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYZNEUTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; RYZNEUTA”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMPLICITY SPYRAL RENAL DENERVATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; Symplicity Spyral Renal Denervation System”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMAAVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; IMAAVY”
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRYVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; TRYVIO”
The Centers for Disease Control and Prevention (CDC), as part of its continuing efforts to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled, Evaluation of the Supporting Young Breast Cancer Survivors, Metastatic Breast Cancer
Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”